Corporate Report

Overview

The report presents Seikagaku's glycoscience-focused pharmaceutical and LAL businesses, including the launch of JOYCLU and expansion of CDMO activities following the Dalton acquisition. Fiscal 2021 consolidated net sales reached ¥34,851 million, up 25.7%, driven by royalty income, LAL and overseas products. It identifies six material issues and describes a Sustainability Promotion Committee, TCFD disclosure and a 33.6% FY2030 CO2 reduction target on a non-consolidated basis. The report also highlights the PyroSmart NextGen recombinant reagent and horseshoe crab conservation activities.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 April 2021 – 31 March 2022
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services